Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2A known ✓ | Q12879 | 2/20 | 0.97 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.97 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.97 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.97 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.97 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.97 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.97 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.97 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.97 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.97 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.97 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19242786 | 0.98 | GRIN2D (1.00) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL19242764 | 0.97 | GRIN2D (0.97) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL19242714 | 0.84 | GRIN2D (0.74) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL9765029 | 0.81 | GRIN2D (0.70) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL23068594 | 0.80 | GRIN2D (0.68) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL5328724 | 0.80 | GRIN2D (0.68) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL30151574 | 0.79 | GRIN2D (0.67) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL19242654 | 0.79 | GRIN2D (0.67) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL1261302 | 0.78 | GRIN2D (0.65) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL29604371 | 0.76 | GRIN2D (0.62) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616807-B2 | Medical counter measures including dry powder formulations and associated methods | Belhaven BioPharma Inc. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12274761-B2 | Compositions and methods to detect GLUA1 in brain and to identify the presence of GLUA1-mediated PTSD | NEUROVATION LABS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20240299680-A1 | MEDICAL COUNTER MEASURES INCLUDING DRY POWDER FORMULATIONS AND ASSOCIATED METHODS | Belhaven BioPharma Inc. (US) | 2024-09-12 | — | — | US | disclosed |
| US-12005185-B2 | Medical counter measures including dry powder formulations and associated methods | Belhaven BioPharma Inc. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20230191047-A1 | MEDICAL COUNTER MEASURES INCLUDING DRY POWDER FORMULATIONS AND ASSOCIATED METHODS | Belhaven BioPharma Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023114462-A1 | MEDICAL COUNTER MEASURES INCLUDING DRY POWDER FORMULATIONS AND ASSOCIATED METHODS | Belhaven BioPharma Inc. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-11439715-B2 | Compositions and methods to detect GLUA1 in brain and to identify the presence of GLUA1-mediated post-traumatic stress disorder and other neurological disorders | NEUROVATION LABS, INC. (US) | 2022-09-13 | — | — | US | disclosed |
| US-20220125956-A1 | COMPOSITIONS AND METHODS TO DETECT GLUA1 IN BRAIN AND TO IDENTIFY THE PRESENCE OF GLUA1-MEDIATED PTSD | NEUROVATION LABS, INC. | 2022-04-28 | — | — | US | disclosed |
| US-20210069358-A1 | COMPOSITIONS AND METHODS TO DETECT GLUA1 IN BRAIN AND TO IDENTIFY THE PRESENCE OF GLUA1-MEDIATED POST-TRAUMATIC STRESS DISORDER AND OTHER NEUROLOGICAL DISORDERS | NEUROVATION LABS INC (US) | 2021-03-11 | — | — | US | disclosed |
| US-20200030304-A1 | MITIGATION OF CNS DISORDERS BY COMBINATION THERAPY USING NEUROSTEROIDS, AND AMPA BLOCKERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-01-30 | — | — | US | disclosed |
| WO-2019046240-A1 | COMPOSITIONS AND METHODS TO DETECT GLUA1 IN BRAIN AND TO IDENTIFY GLUA1-MEDIATED POST-TRAUMATIC STRESS DISORDER | NEUROVATION LABS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2018169798-A9 | MITIGATION OF CNS DISORDERS BY COMBINATION THERAPY USING NEUROSTEROIDS, AND AMPA BLOCKERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-10-18 | — | — | WO | disclosed |
| WO-2018169798-A1 | MITIGATION OF CNS DISORDERS BY COMBINATION THERAPY USING NEUROSTEROIDS, AND AMPA BLOCKERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200030304-A1 | MITIGATION OF CNS DISORDERS BY COMBINATION THERAPY USING NEUROSTEROIDS, AND AMPA BLOCKERS | GABRA4, GABRG1, GABRB2 | GRIN2A 31/4885GRIN2D 82/4885GRIN3B 51/4885 |
| US-20210069358-A1 | COMPOSITIONS AND METHODS TO DETECT GLUA1 IN BRAIN AND TO IDENTIFY THE PRESENCE OF GLUA1-MEDIATED POST-TRAUMATIC STRESS DISORDER AND OTHER NEUROLOGICAL DISORDERS | GRIA1, GRIA2, GRIA3 | GRIN2A 6/4885GRIN2D 25/4885GRIN3B 19/4885 |
| US-12616807-B2 | Medical counter measures including dry powder formulations and associated methods | ADRB2, ADRB3, MC5R | GRIN2A 568/4885GRIN2D 406/4885GRIN3B 499/4885 |
| US-12274761-B2 | Compositions and methods to detect GLUA1 in brain and to identify the presence of GLUA1-mediated PTSD | GRIA1, GRIA2, GRIA3 | GRIN2A 6/4885GRIN2D 27/4885GRIN3B 15/4885 |
| US-20220125956-A1 | COMPOSITIONS AND METHODS TO DETECT GLUA1 IN BRAIN AND TO IDENTIFY THE PRESENCE OF GLUA1-MEDIATED PTSD | GRIA1, GRIA2, GRIA3 | GRIN2A 6/4885GRIN2D 27/4885GRIN3B 15/4885 |
| US-11439715-B2 | Compositions and methods to detect GLUA1 in brain and to identify the presence of GLUA1-mediated post-traumatic stress disorder and other neurological disorders | GRIA1, GRIA2, GRIA3 | GRIN2A 6/4885GRIN2D 25/4885GRIN3B 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.